A Multicentre, Randomised, Double[1]blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)
Status: Ongoing
Details
The study purpose is to learn more about benralizumab (the drug that will be tested
in this study) to find out if it may result in an improvement of severe eosinophilic
asthma and associated health problems in children.
Sponsor: AstraZeneca AB
NCT05692180 - IRB#2022-174